Details

Autor(en) / Beteiligte

• Brunner, Andrew M.
• Esteve, Jordi
• Porkka, Kimmo
• Knapper, Steve
• Traer, Elie
• Scholl, Sebastian
• Garcia‐Manero, Guillermo
• Vey, Norbert
• Wermke, Martin
• Janssen, Jeroen J. W. M.
• Narayan, Rupa
• Fleming, Shaun
• Loo, Sun
• Tovar, Natalia
• Kontro, Mika
• Ottmann, Oliver G.
• Naidu, Purushotham
• Sun, Haiying
• Han, May
• White, Roisin
• Zhang, Na
• Mohammed, Anisa
• Sabatos‐Peyton, Catherine A.
• Steensma, David P.
• Rinne, Mikael L.
• Borate, Uma M.
• Wei, Andrew H.

Titel

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

Ist Teil von

• American journal of hematology, 2024-02, Vol.99 (2), p.E32-E36

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• The safety and efficacy of sabatolimab, a novel immunotherapy targeting T‐cell immunoglobulin domain and mucin domain‐3 (TIM‐3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA‐naive revised International Prognostic System Score (IPSS‐R) high‐ or very high‐risk myelodysplastic syndromes (HR/vHR‐MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR‐MDS. These results support the ongoing evaluation of sabatolimab‐based combination therapy in MDS, CMML, and acute myeloid leukemia.